共查询到20条相似文献,搜索用时 15 毫秒
1.
Human herpesvirus 8 infection DNA positivity is associated with low insulin secretion: A case‐control study in a sub‐Saharan African population with diabetes
下载免费PDF全文
![点击此处可从《Journal of Diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eric Lontchi‐Yimagou Jérôme Legoff Jean‐Louis Nguewa Philippe Boudou Eric V. Balti Jean J. Noubiap Vicky Kamwa Barbara Atogho‐Tiedeu Marcel Azabji‐Kenfack Eric N. Djahmeni Martine Etoa Gaelle Lemdjo Vanessa Balla Mesmin Y. Dehayem Fabienne Foufelle Jean‐Claude Mbanya Jean‐Francois Gautier Eugene Sobngwi 《Journal of Diabetes》2018,10(11):866-873
2.
Maria Mota Simona Georgiana Popa Eugen Mota Adina Mitrea Doina Catrinoiu Dan Mircea Cheta Cristian Guja Nicolae Hancu Constantin Ionescu‐Tirgoviste Radu Lichiardopol Bogdan Mircea Mihai Amorin Remus Popa Cornelia Zetu Cornelia Gabriela Bala Gabriela Roman Cristian Serafinceanu Viorel Serban Romulus Timar Ioan Andrei Veresiu Adrian Radu Vlad 《Journal of Diabetes》2016,8(3):336-344
3.
4.
5.
6.
Effects of different aerobic exercise frequencies on streptozotocin–nicotinamide‐induced type 2 diabetic rats: Continuous versus short bouts and weekend warrior exercises
下载免费PDF全文
![点击此处可从《Journal of Diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nuray Alaca Serap Uslu Guldal Gulec Suyen Umit Ince Mustafa Serteser Hızır Kurtel 《Journal of Diabetes》2018,10(1):73-84
7.
Glycemic status and chronic kidney disease in Chinese adults: Findings from the REACTION study
下载免费PDF全文
![点击此处可从《Journal of Diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lin Lin Jieli Lu Lulu Chen Yiming Mu Zhen Ye Chao Liu Gang Chen Lixin Shi Jiajun Zhao Qiang Li Tao Yang Li Yan Qin Wan Shengli Wu Yan Liu Guixia Wang Zuojie Luo Xulei Tang Yanan Huo Zhengnan Gao Qing Su Youmin Wang Guijun Qin Huacong Deng Xuefeng Yu Feixia Shen Li Chen Liebin Zhao Yu Xu Min Xu Kui Peng Rui Du Meng Dai Mian Li Tiange Wang Zhiyun Zhao Shenghan Lai Donghui Li Yufang Bi Weiqing Wang Guang Ning 《Journal of Diabetes》2017,9(9):837-845
8.
Anoop Misra Hema Gopalan Ranil Jayawardena Andrew P. Hills Mario Soares Alfredo A. Reza‐Albarrán Kaushik L. Ramaiya 《Journal of Diabetes》2019,11(7):522-539
There has been a rapid escalation of type 2 diabetes (T2D) in developing countries, with varied prevalence according to rural vs urban habitat and degree of urbanization. Some ethnic groups (eg, South Asians, other Asians, and Africans), develop diabetes a decade earlier and at a lower body mass index than Whites, have prominent abdominal obesity, and accelerated the conversion from prediabetes to diabetes. The burden of complications, both macro‐ and microvascular, is substantial, but also varies according to populations. The syndemics of diabetes with HIV or tuberculosis are prevalent in many developing countries and predispose to each other. Screening for diabetes in large populations living in diverse habitats may not be cost‐effective, but targeted high‐risk screening may have a place. The cost of diagnostic tests and scarcity of health manpower pose substantial hurdles in the diagnosis and monitoring of patients. Efforts for prevention remain rudimentary in most developing countries. The quality of care is largely poor; hence, a substantial number of patients do not achieve treatment goals. This is further amplified by a delay in seeking treatment, “fatalistic attitudes”, high cost and non‐availability of drugs and insulins. To counter these numerous challenges, a renewed political commitment and mandate for health promotion and disease prevention are urgently needed. Several low‐cost innovative approaches have been trialed with encouraging outcomes, including training and deployment of non‐medical allied health professionals and the use of mobile phones and telemedicine to deliver simple health messages for the prevention and management of T2D. 相似文献
9.
Prevalence of diabetes and impaired fasting glucose in Costa Rica: Costa Rican National Cardiovascular Risk Factors Survey, 2010
下载免费PDF全文
![点击此处可从《Journal of Diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Roy Wong‐McClure Edward W. Gregg Alberto Barcelo Laura Sanabria‐Lopez Kahye Lee Leandra Abarca‐Gomez Marvin Cervantes‐Loaiza Elizabeth T. Luman 《Journal of Diabetes》2016,8(5):686-692
10.
Hypoglycemia is a frequent occurrence in patients with diabetes who are treated with insulin and insulin secretagogues. Hypoglycemia is the limiting factor that prevents patients from achieving the glycemic control known to reduce the microvascular complications of diabetes. Recurrent episodes of hypoglycemia can lead to impaired awareness of hypoglycemia where the first symptom of a low blood sugar is unconsciousness. The fear of hypoglycemia has a significant effect on the quality of life of patients and their families. In the acute setting, hypoglycemia can kill, and clinical trials have demonstrated that a single episode of severe hypoglycemia increases the risk of subsequent mortality and cardiovascular events. Clinicians must make efforts to recognize and prevent hypoglycemia in order to prevent the adverse events associated with this event. Patient education is central to these efforts. Recent developments in glucose monitoring and drug development have provided more approaches that can be used to reduce the risk of hypoglycemia in patients with diabetes. 相似文献
11.
12.
13.
14.
15.
16.
Demographic and clinical characteristics of patients with type 1 diabetes mellitus: A multicenter registry study in Guangdong,China
下载免费PDF全文
![点击此处可从《Journal of Diabetes》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Daizhi Yang Hongrong Deng Guochun Luo Ge Wu Shaoda Lin Lin Yuan Meilun Xv Shaoqing Li Xiuwei Zhang Jianneng Wu Jiangming Lang Ganxiong Liang Jiancai Lin Dingyu Chen Lu Li Yishan Fang Yongxin Wu Wenxin Ou Jin Li Jianping Weng Jinhua Yan 《Journal of Diabetes》2016,8(6):847-853
17.
José Silva‐Cardoso Omar Sheikh Mouhamed Nashawi Son Pham Kelly M. Gallegos Laith R. Dinkha Robert J. Chilton 《Journal of Diabetes》2020,12(4):279-293
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs that were primarily developed for the treatment of type 2 diabetes mellitus. However, these agents have shown to provide additional beneficial effects. We will discuss three main topics regarding the use of SGLT2 inhibitors: noncardiovascular effects, cardiovascular benefits, and novel clinical indications. Multiple clinical trials and preliminary studies across varying disciplines have shown that these agents exhibit cardiorenal‐protective benefits, retinoprotective benefits, and may aid in weight loss without causing marked hypoglycemia. Therefore, these agents represent an avenue in clinical practice to manage comorbid conditions in the hyperglycemic patient. Because of their multifaceted effects and robust action, SGLT2 inhibitors represent therapy options for providers that not only provide beneficial clinical results but also reduce total patient drug burden. 相似文献
18.
Chunyan Hu Yiming Mu Qin Wan Yingfen Qin Ruying Hu Lixin Shi Qing Su Xuefeng Yu Li Yan Guijun Qin Xulei Tang Gang Chen Zhengnan Gao Guixia Wang Feixia Shen Zuojie Luo Li Chen Yanan Huo Qiang Li Zhen Ye Yinfei Zhang Chao Liu Youmin Wang Shengli Wu Tao Yang Huacong Deng Lulu Chen Jiajun Zhao Jieli Lu Lin Lin Mian Li Rui Du Min Xu Yu Xu Tiange Wang Zhiyun Zhao Yuhong Chen Donghui Li Yufang Bi Weiqing Wang Guang Ning for the REACTION Study Group 《Journal of Diabetes》2020,12(1):10-20
19.